VASCVERSA
VascVersa is a med-tech company specializing in vascular regeneration.
VASCVERSA
Industry:
Health Care
Founded:
2018-01-01
Address:
Belfast, Belfast, United Kingdom
Country:
United Kingdom
Website Url:
http://www.vascversa.org
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
500 K GBP
Technology used in webpage:
Euro Wix Wix DNS
Similar Organizations
Fesia Technology
Wearable soft robotics for neural recovery
IntoCare
IntoCare is a high-tech company specializing in surgical products.
Renalyx Health Systems
Renalyx Health Systems is a health care company specializing in comprehensive renal care, and dialysis treatment.
Current Employees Featured
Investors List
QUBIS
QUBIS investment in Seed Round - VascVersa
HBAN
HBAN investment in Seed Round - VascVersa
Co-FundNI
Co-FundNI investment in Seed Round - VascVersa
Co-FundNI
Co-FundNI investment in Seed Round - VascVersa
QUBIS
QUBIS investment in Seed Round - VascVersa
HBAN
HBAN investment in Seed Round - VascVersa
Official Site Inspections
http://www.vascversa.org
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.186
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "VascVersa"
Regenerative Medicine | Vascversa
Vascversa is a Regenerative Medicine Company developing exciting new cell therapies that promote vascular regeneration and repair. Spun out of Queen's University Belfast and built on …See details»
VascVersa - Crunchbase Company Profile & Funding
VascVersa is a med-tech company specializing in vascular regeneration. A cell therapy technology aimed at regenerating blood vessels to improve blood supply and facilitate long …See details»
VascVersa Ltd - LinkedIn
VascVersa is new Regenerative Medicine company recently spun out from Queen's University in Belfast. Our Vision is to commercialise living medicines to reinvigorate patients lives. Utilising...See details»
NI’S FIRST CELL THERAPY COMPANY VASCVERSA SECURE SIX …
Cell therapies are at the forefront of medical innovation and are recognised as one of the leading technologies to drive novel treatments. The company’s first target is “non–healing wounds” …See details»
Second-Round-Investment - vascversa.com
• VascVersa, a spin-out from the Queen’s University Belfast, has secured its second funding round, raising over £0.5 million. • VascVersa is developing a new class of cell therapy, …See details»
News (All) - Vascversa
VascVersa is delighted to work with Alcyomics. The Newcastle based company are highly experienced experts in determining the safety of therapeutic products including advanced …See details»
Cell Therapy for Blood Supply | (HIRANI) Health Innovation …
Sep 19, 2024 · VascVersa is currently developing a novel cell therapy for the treatment of diseases that are complicated by poor blood supply, also known as ischaemic diseases. “Our …See details»
NI's first cell therapy firm VascVersa secures six-figure deal
May 17, 2021 · Queen’s University spin-out VascVersa has completed a six-figure deal in its first investment round, which will allow the company to further develop technology to repair …See details»
VascVersa - ICURe Programme
VascVersa is developing a new cell therapy for the treatment of conditions which currently cost the NHS over £1 billion each year. Almost half a million people in the UK suffer from chronic non-healing wounds, in particular, diabetic foot …See details»
Queen’s spin-out VascVersa secures £500,000 to shake …
Aug 8, 2022 · VascVersa, a medtech spin-out from Queen’s University Belfast, has secured more than £500,000 in fresh funding. This will be used to accelerate the development of a novel cell therapy to promote...See details»
Sync NI - VascVersa completes second investment round to …
Aug 8, 2022 · VascVersa, an award winning, early-stage regenerative medicine spin out from Queen’s University in Belfast, has completed its second seed funding round, raising over …See details»
VascVersa - Case Studies | ICURe NorthByNorthwest
VascVersa commercialises Advanced Therapy Medicinal Products (ATMPs) derived from the novel Angicyte™ technology. Cell therapies are at the forefront of medicine and are …See details»
VascVersa - Products, Competitors, Financials, Employees, …
VascVersa is a regenerative medicine company focused on developing cell therapies for vascular regeneration and repair. Use the CB Insights Platform to explore VascVersa's full profile.See details»
Belfast’s VascVersa raises funding round for its cell therapy
May 17, 2021 · VascVersa is developing a cell treatment for vascular regeneration to repair damaged blood vessels. Its technology stimulates new blood vessel formation to improve …See details»
Second £500,000 funding round for VascVersa – The Irish News
Aug 9, 2022 · VascVersais developing a cell therapy product as a new treatment for vascular regeneration, and the latest investment will allow it to accelerate the development of its ground …See details»
Belfast’s VascVersa raises funding round for its cell therapy
May 19, 2021 · VascVersa is developing a cell treatment for vascular regeneration to repair damaged blood vessels. Its technology stimulates new blood vessel formation to improve …See details»
VascVersa Company Profile 2024: Valuation, Funding & Investors
Developer of regenerative medicine designed to deliver new cell therapies that promote vascular regeneration and repair.See details»
QUB med-tech spin out VascVersa lands six-figure investment deal
May 18, 2021 · QUEEN’S University spin out VascVersa has completed a six-figure deal in its first investment round led by QUBIS, the commercialisation arm of the third level institution.See details»
VascVersa (@vascversa) / Twitter
Feb 13, 2020 · VascVersa is a regenerative medicine company, seeking to deliver a new, exciting cell therapy to treat ischaemic diseases and promote rapid wound repair.See details»
VascVersa - Raised $951K Funding from 5 investors - Tracxn
Nov 5, 2024 · VascVersa has raised a total funding of $951K over 3 rounds from 5 investors. Investors include Gov.uk, Clarendon Fund Managers and 3 others. Their latest funding round …See details»